A Study to Evaluate the Effect of a Potent Cytochrome P450 (CYP) 3A Inhibitor on Ipatasertib
Status:
Completed
Trial end date:
2017-09-06
Target enrollment:
Participant gender:
Summary
This study will be a single center, open-label, 2-period, fixed-sequence, Phase 1 drug-drug
interaction study in healthy subjects. The primary purpose of this study is to evaluate the
effect of itraconazole on the PK of ipatasertib and its primary metabolite (G-037720).